Aurobindo Pharma Ltd's Q2FY17 consolidated net profit rises 33.48% yoy to Rs.606 crore : Estimates Mixed

India Infoline Research Team | November 15, 2016 09:10 IST

Aurobindo Pharma Ltd Q2FY17

Consolidated Results Q2FY17: (Rs. in crore)

Q2FY17 YoY (%)
Revenue 3,775 12.2
EDITDA 929 19.3
EBITDA Margin (%) 24.6 146
Net Profit (adjusted) 606 33.5
***EBITDA margin change is bps

Aurobindo Pharma Ltd’s Q2FY17 consolidated numbers came in mixed from our estimates. Revenue was 2.1% down from our estimates of Rs 3856.7 cr.  Company’s EBITDA was 0.9% below the estimated figure of Rs 937 cr. Company’s net profit however, stood 0.6% above the estimates of Rs 602 cr.

Company’s net revenue stood at Rs 3775.5 cr which grew 12.2% during the corresponding quarter of previous year. Company's formulation sales to USA grew 17.8% yoy to Rs 1735.1 cr. Moreover, revenues from Betalactum API (Active Pharmaceutical Ingredients) grew 19.6% yoy to Rs 511.3 cr.

EBITDA surged by 19.3% yoy to Rs 929 cr and EBITDA margins expanded 146 bps yoy to 24.6%.

Company's net profit rose 33.5% yoy to Rs 605.65 cr. This was driven by 27% yoy drop in finance costs.



Technical View:

Aurobindo Pharma Ltd ended at Rs. 792, up by 20.1 points or 2.6% from its previous closing of Rs. 771.9 on the BSE.
The scrip opened at Rs. 792 and touched a high and low of Rs. 792 and Rs. 792 respectively. A total of 8453(NSE+BSE) shares were traded on the counter. The stock traded above its 50 DMA.

BSE 719.40 [24.10] ([3.24]%)
NSE 719.55 [23.60] ([3.18]%)

***Note: This is a NSE Chart

 

Advertisements

  • Get your free IIFL Demat & Trading A/c now...Click here
  • Get IIFL express personal loan disbursal in just 8* hours...Know More
  • Get the most detailed result analysis on the web - Real Fast!
  • Actionable & Award-Winning Research on 500 Listed Indian Companies.